How does KY19382 actually stimulate dormant hair follicles to grow again?

Awakening What Was Thought to Be Lost

Hair follicles are miniature organs embedded in the scalp. Even after visible hair falls out, the follicle itself often remains beneath the skin. These follicles can stay in a prolonged resting state known as telogen, when no visible hair is produced. In androgenetic alopecia (commonly called male and female pattern baldness), follicles progressively shrink, produce thinner hairs, and eventually appear dormant. The central question for researchers—and for us, if we experience thinning hair—is whether these follicles are truly gone or can be reawakened. KY19382 has been proposed as an experimental compound that may provide an answer.

To understand what makes KY19382 different, we need to focus on the Wnt/β-catenin pathway. This pathway is a form of communication between cells. It works by sending signals that tell the follicle when to start growing hair (the anagen phase) and when to stop. In many forms of hair loss, the activity of Wnt/β-catenin is reduced, which traps follicles in a resting state. In cell and mouse experiments, KY19382 reactivated this pathway and restarted growth in resting mouse follicles; whether it does this in human scalp is untested. This is important because unlike minoxidil—which mainly improves blood flow around the follicle—KY19382 directly targets the molecular signals that control follicle behavior.

From Mice to Human Follicles: What Research Shows

The main peer-reviewed study on KY19382 and hair was published in 2021 in the British Journal of Pharmacology by Ryu and colleagues. In this research, the compound was tested in cultured cells, in isolated human hair follicles and in mice. The design provides us with clues, but also clear limitations. The paper discloses that the senior author is chief executive of CK Biotech, the company that holds the licence to develop the compound.

The study applied KY19382 topically to mice of the C57BL/6 strain, whose hair cycles are well studied, daily for 14 or 28 days (5 mice per group). It also treated human scalp follicles in culture for 3 days and mouse whisker follicles for 6 days. Hair regrowth in mice was evaluated with photographs, the weight of regrown hair and tissue analysis; in cultured follicles the team measured elongation. In mice, KY19382 produced more regrowth than minoxidil at 28 days. The cultured human follicles grew longer than untreated ones; the paper's statistics for human follicles compare KY19382 only with no treatment. However, we must be critical here: the experiments were short-term, did not involve real patients with hair loss, and the complexity of a living human scalp cannot be fully reproduced in either mice or isolated follicle cultures.

Why This Matters for Dormant Follicles

In mice, KY19382 both reactivated resting follicles and, in wound and cell-patch models, led to the formation of new ones (Ryu et al., 2021); none of this has been shown in people. By amplifying Wnt/β-catenin signals, follicles could in theory be pushed back into an active growth phase. This mechanism makes it different from drugs like minoxidil and finasteride, which work indirectly or by blocking hormones. Whether this applies to follicles in human pattern hair loss is unknown. The laboratory data are a first step, not a guarantee.

Still Experimental, With Questions Ahead

As of today, KY19382 remains an experimental molecule. It has not received approval from the U.S. Food and Drug Administration (FDA) or any other regulatory body. That means no long-term human trials have yet confirmed its safety or sustained effectiveness. For those of us looking for a reliable treatment, this is a critical limitation. What works in a dish or in a mouse does not always translate to humans. Moreover, overactivation of the Wnt/β-catenin pathway has been linked to abnormal tissue growth and even tumor formation in other contexts, which is why rigorous safety trials are essential before any clinical use.

KY19382 appears to stimulate dormant follicles by turning back on the Wnt/β-catenin pathway, a key growth signal that determines when hair starts growing again. In one company-linked study, KY19382 produced more hair regrowth than minoxidil in mice at 28 days (5 mice per group) and lengthened cultured human follicles over three days compared with no treatment (Ryu et al., 2021). It has never been tested in people. However, the research is still at an early stage, short in duration, and far from demonstrating long-term safety or effectiveness in people. For now, KY19382 remains a promising experimental compound—not a proven therapy.

References

Ryu, Y. C., Lee, D. H., Shim, J., et al. (2021). KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis. British Journal of Pharmacology, 178(12), 2533–2546. https://doi.org/10.1111/bph.15438 (PMID 33751552)

National Institutes of Health (NIH). (2021, March 8). Understanding hair loss: Causes and treatments. Retrieved from https://www.nih.gov/news-events/nih-research-matters/understanding-hair-loss-causes-treatments